This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Evaluation and Medico-Economic Study of FIBROSCAN in Patients With Viral Hepatitis

Sponsored by Assistance Publique - Hôpitaux de Paris

About this trial

Last updated 16 years ago

Study ID

IC0504

Status

Terminated

Type

Observational

Placebo

No

Accepting

18-75 Years
18+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 17 years ago

What is this trial about?

A new approach to the evaluation of liver fibrosis has been proposed using PULSOMETRY. The objective is to evaluate the diagnostic performances of the FIBROSCAN technique, together with non-invasive techniques, and to determine how it is able to predict the histological fibrosis score, defined by the METAVIR score. This transversal study aims to compare the evaluation of hepatic fibrosis obtained by FIBROSCAN and histology (METAVIR score) in 2550 consecutive patients taken in charge for a liver biopsy. The results of the study will compare the respective performances of these techniques in the prediction of the METAVIR score, and help in the recommendation of the care of patients with viral hepatitis B and C; these methods will undergo a medico-economic study.

What are the participation requirements?

Yes

Inclusion Criteria

- Chronic hepatitis B or C

- With liver biopsy indication

- Patient information

No

Exclusion Criteria

- Drug hepatitis

- Metabolic hepatology

- Steatosis or non-alcoholic steatohepatitis

- Autoimmune hepatopathy

- Non-contraindication to liver biopsy

- Non-contraindication to FIBROSCAN examination

- Ascites

- Obesity

Locations

Location

Status